Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of General Practitioners ; (6): 535-540, 2019.
Artigo em Chinês | WPRIM | ID: wpr-755964

RESUMO

Objective To investigate the efficacy of rosuvastatin combined with silibinin capsule in treatment of hyperlipidemic patients with nonalcoholic fatty liver disease.Methods One hundred and nineteen hyperlipidemic patients with non-alcoholic fatty liver disease admitted in hospital from January 2016 to March 2017 were randomly assigned into two groups:60 patients received rosuvastatin(10 mg,q.d) and silibinin capsules(70 mg,t.i.d.,study group) and 59 patients received starch tablets(10 mg,q.d) and silibinin capsules(70 mg,t.i.d.,control group).The blood lipid,liver function,inflammatory factors,liver CT value,the specific CT value of liver and spleen were compared at baseline and 6 months after intervention.Results Compared to baseline values,the levels of total cholesterol (TC),triglyceride (TG),alanine aminotransferase (ALT),γ-glutamyltranspeptidase (GGT),TNF-α,IL-6,and CRP were decreased (t=2.44,2.04,2.48,6.95,2.38,2.78,3.97,all P<0.05);and the levels of HDL-C,liver CT value,liver/spleen CT value ratio were increased (t=5.44,2.26,2.08,all P<0.05) after treatment in study group.The improvement of TG,LDL-C,ALT,GGT,TNF-α,CRP,liver CT value,liver/spleen CT value ratio were more marked than those of the control group (P<0.05) (t=1.92,2.65,2.02,5.62,2.11,2.20,2.22,2.08,all P<0.05).The effective rate of study group was higher than that of the control group[98.2%(55/56) vs.85.7%(48/56),x2=2.05,P=0.04];the adverse reactions were similar in two groups.Conclusion Compared with silibinin alone,rosuvastatin combined with silibinin capsules is more effective in treatment of hyperlipidemic patients with nonalcoholic fatty liver disease,which can significantly improve the blood lipids,liver function,inflammatory response and aliphatic degree without increase of adverse reaction.

2.
Chinese Journal of Biochemical Pharmaceutics ; (6): 254-256, 2017.
Artigo em Chinês | WPRIM | ID: wpr-614076

RESUMO

Objective To investigate the clinical effect of amlodipine combined with Telmisartan Capsules in the treatment of hypertension.MethodsThe patients with primary hypertension in 87 cases in the second hospital affiliated to Tianjin Medical University were divided into two groups.43 patients in control group were treated with amlodipine 2.5~5mg/d orally, 44 patients in the experimental group on the basis of combined with Telmisartan Capsules 40~80mg/d orally, the total course of treatment was eight weeks.The changes of blood pressure levels were compared before and after treatment, the effective rate of the treatment and adverse reactions after treatment, to evaluate the clinical efficacy of amlodipine combined with Telmisartan Capsules in the treatment of hypertension.ResultsAfter treatment, two groups of three blood pressure index were significantly decreased (P<0.05), compared with the control group, the experimental group of patients with treatment After treatment the blood pressure level is low(P<0.05).After eight weeks of treatment, the total efficiency of control group was 72.09%, the total efficiency of experimental group was 95.45%, the experimental group was higher than that in the control group (P<0.05) after treatment, patients in the control group with two cases of headache (4.65%), two cases of lower extremity edema (4.65%);the experimental group of two cases of vertigo (4.55%), three cases of joint pain (6.82%), there was no significant difference in total adverse reaction rate between the two groups.Conclusion Amlodipine combined with Telmisartan Capsules in the treatment of hypertension has good clinical effect.

3.
Chinese Journal of Biochemical Pharmaceutics ; (6): 278-279, 2017.
Artigo em Chinês | WPRIM | ID: wpr-611287

RESUMO

Objective To investigate the clinical value and safety of cedilanid, esmolol in the treatment of atrial fibrillation. Methods From August 2014 to August 2016 our Hospital from 117 patients with atrial fibrillation clinical data, according to the random number distribution principle, the patients were divided into observation group 59 cases and control group of 58 cases, all patients were given the treatment of primary disease, the clinical symptoms, the patients in the observation group were given oxygen, has given furosemide, cedilanid, after micro injection pump intravenous nitroglycerin, 5-20 g/min. Start after the injection of nitroglycerin, establish another vein channel, every 30 min to 0.2 mg patients, the treatment group were treated with intravenous injection of small dose esmolol. The clinical efficacy, ventricular rate, systolic blood pressure, diastolic blood pressure and adverse reactions were observed in two groups. Results The early and late effective rates of the two groups were not significantly different. The observation showed that after treatment, the ventricular rate, systolic pressure and diastolic pressure in the observation group were significantly higher than those in the control group (P<0.05), and the incidence of adverse reactions in the two groups was significantly different (P<0.05). Conclusion High dose cedilanid combined with small dose esmolol in treatment of atrial fibrillation, obvious curative effect, high safety, can choose the appropriate application.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA